ORPHA:98826
Myelodysplastic neoplasm with low blasts
Also known as: MDS-LB · Refractory anemia
Publications
8,077
Trials
63
Interventional, condition-specific
Researchers
1,601
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Refractory cytopenias with unilineage (RCUD) is a frequent low-risk subtype of myelodysplastic syndrome (MDS) characterized by refractory cytopenias associated with limited to one cell lineage.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005272
- MeSH:D000753
- UMLS:C2826318
- NCIT:C2872
- NCIT:C82591
Additional Mondo synonyms (5)
MDS with single lineage dysplasia · MDS-SLD · RA · refractory anaemia · refractory anemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
8,077 matched papers (2,735 in last 10 years) Source
- Phenotype characterisedPresent
14 HPO annotations (e.g. Anemia of inadequate production; Macrocytic anemia; Normocytic anemia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
63 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
14
Associated phenotypes · MONDO:0005272
- Anemia of inadequate production
- Macrocytic anemia
- Normocytic anemia
- Abnormal cardiac ventricular function
- Thrombocytopenia
Showing 5 of 14 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0005272
- DEFERIPRONE·phase 3
- DEFEROXAMINE·phase 3
CTD chemicals (MyDisease.info)
1 associated chemical · 66 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Azathioprine · marker/mechanism
Pathways: Antifolate resistance; MAPK signaling pathway; Cytokine-cytokine receptor interaction; NF-kappa B signaling pathway; Sphingolipid signaling pathway; mTOR signaling pathway; Apoptosis; TGF-beta signaling pathway
Literature
Is anyone studying this?
8,077
8,077 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
8,077 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,735 in the last 10 years · low confidence
Phrase hits: 8,068 · MeSH hits: 17
Who's working on it?
1,601
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y8 papers · 2026
The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China.
Papers in Europe PMC - 02Wang H7 papers · 2026
Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Papers in Europe PMC - 03Germing U5 papers · 2026
Department of Hematology, Oncology and Clinical Immunology Heinrich-Heine-Universität Düsseldorf Germany.
Papers in Europe PMC - 04Guo J5 papers · 2026
Department of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Papers in Europe PMC - 05Hou HA5 papers · 2026
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw.
Papers in Europe PMC - 06Jin J5 papers · 2026
Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. jiej0503@zju.edu.cn.
Papers in Europe PMC - 07Shi C5 papers · 2024
Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, PR China.
Papers in Europe PMC - 08Tien HF5 papers · 2026
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Papers in Europe PMC - 09Tsai XC5 papers · 2026
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Papers in Europe PMC - 10Chang C4 papers · 2026
Department of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
63
interventional trials for this specific condition
63 interventional trials matched this specific condition name; 4 currently recruiting in our sample.
Data as of 11 September 2026
63 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.7th percentile).
low confidence · 97.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
63 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03314974·RECRUITING·Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Not reviewed·Conditions: Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Lymphoma·Matched via name phrase
- NCT06802055·RECRUITING·Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
Not reviewed·Conditions: Aplastic Anaemia·Matched via MeSH
- NCT07299123·ENROLLING BY INVITATION·Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
Not reviewed·Conditions: Severe Aplastic Anemia (SAA) · Severe Aplastic Anemia, Refractory · Severe Aplastic Anemia·Matched via MeSH
- NCT07712562·NOT YET RECRUITING·A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
Not reviewed·Conditions: Bone Marrow Failure Syndromes · Aplastic Anemias · Severe Aplastic Anemia (SAA) · Severe Aplastic Anemia, Relapse·Matched via MeSH
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 20 · after dedupe 19 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 19 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (19)
- isrctn·ISRCTN31682779·No longer recruiting·A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14695157·Recruiting·A study to test the safety of INCB160058 in participants with blood cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90362708·Recruiting·Bleximenib absorption, metabolism, and excretion in participants with acute leukemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10023611·Recruiting·A study of JNJ-80948543 in combination with other CD3 T-cell engagers in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-Cell NHL)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12278036·No longer recruiting·A study of bleximenib in combination with acute myeloid leukemia-directed therapies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17568633·No longer recruiting·A study to evaluate safety, interaction with the body (pharmacokinetics), and clinical activity of combination of RO6870810 and venetoclax, with or without rituximab, in participants with cancer of the white blood cells (lymphoma)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11885863·No longer recruiting·Investigating the safety and efficacy of a Universal CAR-T cell immunotherapy in patients with relapse and refractory B-cell acute lymphoblastic leukemia and B lymphoblastic lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14054375·Recruiting·A Phase III randomized, double-blinded, placebo-controlled trial to investigate the impact of intra-coronary transfusion of G-CSF mobilized autologous circulating hematopoietic stem/progenitor cells (CPC) therapy in patients with diffuse coronary artery disease who are not candidates for coronary artery intervention
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12785009·No longer recruiting·Effects of Jinghuaweikang capsule combined quadruple therapy on the refractory infection of Helicobacter pylori
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49958132·No longer recruiting·Aspiration Therapy for treatment of obesity with AspireAssist™ Aspiration Therapy System
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14207975·No longer recruiting·International study on the treatment of pediatric relapsed acute myeloid leukemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26002902·No longer recruiting·Intra-coronary transfusion of autologous CD34+ cells improves left ventricular function in patients with diffuse coronary artery disease (CAD) and non-candidates for coronary artery intervention
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59395590·No longer recruiting·MUK six
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20957055·No longer recruiting·Role of diastolic dysfunction in the pathogenesis of dialytic associated hypotension and effect of systematic colloid infusion in refractory cases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90301130·No longer recruiting·Treatment of Diabetic Foot Wounds by Vacuum-Assisted Closure (VAC®)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29686154·No longer recruiting·Prevention of catheter-related deep vein thrombosis with nadroparin in hemato-oncology patients treated with high-dose chemotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70542454·No longer recruiting·Reduced intensity chemotherapy given with and without imatinib mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T): a randomized phase II study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62207270·No longer recruiting·Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukaemia or myelodysplastic syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64649191·No longer recruiting·Acute myeloid leukaemia (AML) trial 12 (protocol for children)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Myelodysplastic neoplasm with low blasts — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Myelodysplastic neoplasm with low blasts" OR "MDS-LB" OR "Refractory anemia" OR "MDS with single lineage dysplasia" OR "MDS-SLD" OR "refractory anaemia"
MeSH descriptor terms unioned into the query: Anemia, Refractory
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Myelodysplastic neoplasm with low blasts" OR "MDS-LB" OR "Refractory anemia" OR "MDS with single lineage dysplasia" OR "MDS-SLD" OR "refractory anaemia" OR "Anemia, Refractory"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 63 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: RA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (8077) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T05:29:00.269Z
